Pfizer and BioNTech SE have announced the signing of an agreement with the Ministry of Health in Morocco, Pfizer Inc. and Pfizer SA Laboratories in Morocco, for the supply of their vaccine against Covid-19. As expected by the Ministry of Health in Morocco, deliveries are scheduled for the year 2021.
“We are very honored to collaborate with the Moroccan government. On behalf of Pfizer Laboratories in Morocco, I would first of all like to congratulate the Moroccan authorities for all the decisions and measures taken in the fight against the COVID19 pandemic. We are mobilizing our scientific and manufacturing resources, in favor of our common objective, that of providing the Pfizer BioNTech vaccine against Covid-19 for the Moroccan population ”, said Ali Besri, Regional Director for North Africa and CEO of Pfizer SA Laboratories in Morocco. “In the face of this global health crisis, Pfizer’s mission, which is to bring major breakthroughs that change the lives of patients, takes on its full meaning. Our hope is that our vaccine will help achieve this. “
“I would like to thank the Moroccan government for its support and confidence in our vaccine which, we hope, will help address this global pandemic threat. Our goal is to ensure the global supply of a vaccine against Covid-19 that is well tolerated and effective for a large part of the population who need it around the world, as quickly as possible. “, said Sean Marett, Commercial Director of BioNTech.
Pfizer and BioNTech aim to manufacture a total of more than 3 billion doses of their COVID-19 vaccine worldwide by the end of 2021. To do this, the two laboratories plan to continuously improve processes, a expansion of facilities at manufacturing sites as well as expansion of partnerships with new suppliers and manufacturers.
The vaccine, which is based on BioNTech’s proprietary mRNA (Messenger Ribonucleic Acid) technology, was developed by BioNTech and Pfizer.